Resumen de acción BCDA BioCardia, Inc, empresa de medicina regenerativa en fase clínica, desarrolla en Estados Unidos terapias celulares y derivadas de células para enfermedades cardiovasculares y pulmonares. Saber más
Recompensas Análisis de riesgos + 3 riesgos adicionales
Ver todos los controles de riesgos {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Captura tus ideas, enlaces y narrativas de la empresa
Competidores de BioCardia, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del BioCardia Precios históricos de las acciones Precio actual de la acción US$2.51 Máximo en las últimas 52 semanas US$8.85 Mínimo de 52 semanas US$1.63 Beta 1.3 Cambio en 1 mes 18.04% Variación en 3 meses 6.81% Cambio de 1 año -62.40% Variación en 3 años -92.43% Variación en 5 años -96.22% Variación desde la OPV -98.77%
Noticias y actualizaciones recientes
BioCardia, Inc. Announces Commercial Availability of Morph DNA Steerable Introducer Product Family Dec 18
Third quarter 2024 earnings released: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) Nov 15
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure Oct 28
BioCardia Regains Full Compliance with Nasdaq Capital Market's Listing Requirements Sep 20
New major risk - Shareholder dilution Sep 02
BioCardia, Inc. Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family Aug 29 Ver más actualizaciones
BioCardia, Inc. Announces Commercial Availability of Morph DNA Steerable Introducer Product Family Dec 18
Third quarter 2024 earnings released: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) Nov 15
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure Oct 28
BioCardia Regains Full Compliance with Nasdaq Capital Market's Listing Requirements Sep 20
New major risk - Shareholder dilution Sep 02
BioCardia, Inc. Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family Aug 29
BioCardia, Inc. Announces Fda Approves Cardiamp®? Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment Aug 21
New major risk - Share price stability Aug 20
Consensus EPS estimates fall by 1,024% Aug 20
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 15
New major risk - Revenue and earnings growth Aug 14 BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Aug 10
BioCardia, Inc. Submits for FDA Approval of Morph®? DNA™? Steerable Introducer Product Family Jul 31
BioCardia, Inc. Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure Jul 25
New major risk - Shareholder dilution May 31
First quarter 2024 earnings released: US$0.09 loss per share (vs US$0.17 loss in 1Q 2023) May 16
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable May 14
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial May 03
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort Apr 26
BioCardia, Inc., Annual General Meeting, May 20, 2024 Apr 16
New major risk - Financial position Mar 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 28
BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 21
BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement Mar 13
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study Mar 12
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure Mar 05
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA Feb 08
New major risk - Market cap size Jan 26 BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million. Dec 06
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure Nov 30 BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million. Nov 17
BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure Nov 15
New major risk - Negative shareholders equity Nov 10
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Insufficient new directors Nov 02
BioCardia, Inc. Elects Bill Facteau as Class I Director Oct 19
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns Oct 12
Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii Oct 12
BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market Sep 16
BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market Sep 13
BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs Sep 07
Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial Sep 06
BioCardia, Inc., Annual General Meeting, Oct 18, 2023 Sep 02
Consensus revenue estimates decrease by 74%, EPS upgraded Aug 16
New major risk - Revenue size Aug 11
Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint Aug 11
BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023 Aug 03
New major risk - Share price stability Jul 25
Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected Jul 25
BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency Jul 06
New minor risk - Share price stability Jun 23
Insider recently bought US$177k worth of stock May 28
Consensus revenue estimates increase by 86% May 17
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 12
BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023 May 04
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 31
Price target decreased by 24% to US$7.50 Jan 29 BioCardia, Inc. announced that it expects to receive $3.564989 million in funding Dec 16
BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure Dec 07
Consensus forecasts updated Nov 18
Consensus forecasts updated Nov 17
Price target decreased to US$9.88 Nov 16
Insufficient new directors Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 11
BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 03
Insufficient new directors Nov 02
Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting Sep 15
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial Sep 01
BioCardia stock rises on contract for delivery products for BlueRock's cell therapies Aug 24
Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely? Aug 24
Consensus revenue estimates increase by 138% Aug 17
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 12
BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022 Aug 05
BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies Jun 16
Consensus EPS estimates fall by 15% May 21
Consensus revenue estimates increase by 64% May 18
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 13
Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation May 10
BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022 May 05
Price target decreased to US$10.63 Apr 27
Consensus forecasts updated Apr 13
BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells Apr 13
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 30
Biocardia Receives No Objection Letter from Health Canada, Enabling Company to Expand Cardiamp Cell Therapy Heart Failure Trial into Canada Mar 03
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed Feb 15
BioCardia®, Inc Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure Feb 04
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully Jan 06
Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.30 loss in 3Q 2020) Nov 12
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully Sep 23
BioCardia, Inc. Announces Data from Its CardiAMP® Cell Therapy Heart Failure Pivotal Trial to Present at the Heart Failure Society of America Annual Meeting 2021 on September 11, 2021 Sep 11
Consensus revenue estimates increase to US$145.0k Aug 21
Price target decreased to US$11.17 Aug 13
Second quarter 2021 earnings released: US$0.20 loss per share (vs US$0.46 loss in 2Q 2020) Aug 13
Biocardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies Jul 16 Rentabilidad de los accionistas BCDA US Biotechs Mercado US 7D -2.3% -4.2% 0.2% 1Y -62.4% -3.0% 23.1%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Los resultados de BCDA fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del -3% el año pasado.
Rentabilidad vs. Mercado: BCDA obtuvo unos resultados inferiores a los del mercado US, que fueron del 23.1% el año pasado.
Volatilidad de los precios Is BCDA's price volatile compared to industry and market? BCDA volatility BCDA Average Weekly Movement 12.1% Biotechs Industry Average Movement 11.4% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Precio estable de las acciones: El precio de las acciones de BCDA ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BCDA ha disminuido de 18% a 12% en el último año, pero sigue siendo superior al 75% de los valores de US.
Acerca de la empresa BioCardia, Inc, empresa de medicina regenerativa en fase clínica, desarrolla en Estados Unidos terapias celulares y derivadas de células para enfermedades cardiovasculares y pulmonares. Su principal producto candidato es CardiAMP, un sistema de terapia celular mononuclear autóloga en ensayo clínico de fase III para el tratamiento de la insuficiencia cardiaca isquémica con fracción de eyección reducida y la angina refractaria derivada de la isquemia miocárdica crónica. La empresa también está desarrollando una plataforma de terapia celular alogénica, que es una terapia celular mesenquimal derivada de médula ósea expandida en cultivo en fase I/II de ensayo para tratar la insuficiencia cardiaca isquémica y el síndrome de distrés respiratorio agudo.
Mostrar más Resumen de fundamentos de BioCardia, Inc. ¿Cómo se comparan los beneficios e ingresos de BioCardia con su capitalización de mercado? Estadísticas fundamentales de BCDA Capitalización bursátil US$10.54m Beneficios(TTM ) -US$7.72m Ingresos (TTM ) US$71.00k
162.1x Ratio precio-ventas (PS)
-1.5x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de BCDA Ingresos US$71.00k Coste de los ingresos US$4.13m Beneficio bruto -US$4.06m Otros gastos US$3.67m Beneficios -US$7.72m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -1.68 Margen bruto -5,714.08% Margen de beneficio neto -10,876.06% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado BCDA a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/02/11 08:09 Precio de las acciones al final del día 2025/02/11 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github .
Fuentes analistas BioCardia, Inc. está cubierta por 3 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución James Molloy Alliance Global Partners Joseph Pantginis H.C. Wainwright & Co. Emanuela Branchetti H.C. Wainwright & Co.
